Wire flash
FinanceBoston Scientific beats Q2 estimates on broad sales growth, shares rise over 3% pre-market
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Boston Scientific (NYSE: BSX) reported second-quarter earnings and revenue that exceeded Wall Street expectations, driving shares up over 3% in pre-market trading. The medical device manufacturer posted earnings per share of $0.86, beating the consensus estimate of $0.83, while revenue reached $5.44 billion, surpassing the expected $5.37 billion. Growth was broad-based across both core divisions: the MedSurg segment grew 5.9% and the Cardiovascular segment grew 8.3%. Internationally, Asia-Pacific led with 11.2% sales growth, while Latin America and Canada surged 22.4%. CEO Mike Mahoney highlighted disciplined execution and long-term category leadership strategy. However, the company's full-year EPS guidance of $3.28-$3.32 fell short of the $3.36 consensus, and Q3 guidance of $0.80-$0.82 also missed expectations of $0.84. The company maintained its organic sales growth forecast of 5-6% for the year.
Source report
Fiona Craig Wed, July 29, 2026 at 5:27 AM PDT 2 min read
Boston Scientific (NYSE: BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business.
The company reported earnings of $0.86 per share for the quarter, ahead of analysts' consensus estimate of $0.83.
Revenue increased to $5.44 billion, representing 7% operational and organic growth and surpassing market expectations of $5.37 billion.
Broad-Based Growth Across Business Segments
Boston Scientific delivered growth across both of its core operating divisions during the quarter:
- MedSurg segment: Reported net sales growth of 5.9%, with operational and organic growth of 5.4%.
- Cardiovascular business: Reported net sales growth of 8.3%, with operational and organic growth reaching 7.8%.
International Markets Support Revenue Growth
The company also reported strong performance across its major geographic regions:
- United States: Net sales increased 6.2% on both a reported and operational basis.
- Europe, Middle East and Africa (EMEA): Reported growth of 6.1%, with operational growth of 4.2%.
- Asia-Pacific (APAC): Strongest performance among major regions, with both reported and operational sales increasing 11.2%.
- Latin America and Canada: Revenue climbed 22.4% on a reported basis and 16.2% on an operational basis.
CEO Highlights Long-Term Growth Strategy
Chairman and Chief Executive Officer Mike Mahoney said:
"Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."
Updated Guidance Falls Short of Market Expectations
Despite the stronger-than-expected second-quarter performance, Boston Scientific issued earnings guidance that came in below analysts' forecasts:
- Full-year earnings per share: Expected between $3.28 and $3.32, compared with the consensus estimate of $3.36.
- Full-year organic net sales growth: Forecast at approximately 5% to 6%.
- Third-quarter adjusted earnings per share: Expected between $0.80 and $0.82, below analysts' expectations of $0.84.
- Third-quarter reported and organic net sales growth: Forecast at approximately 3% to 5%.
Boston Scientific stock price
View Comments
Source
Yahoo FinanceWestern
Part of this Story
Boston Scientific Announces Global Restructuring, Q2 Results Beat Estimates